An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors
ESK-440 was safe and tolerable with a maximum tolerated dose of 500mg daily; however, the study was terminated early based on sponsor decision.
Authors
- Manish R. Sharma (ORCID: https://orcid.org/0009-0000-9769-0850)
- Drew Rasco (ORCID: https://orcid.org/0009-0009-6619-2854)
- Russell J. Schilder
Institutions
- Thomas Jefferson University (US)
- Sidney Kimmel Cancer Center (US)
- South Texas Accelerated Research Therapeutics (US)
- Star Center (US)
Publication Details
- Journal
- Neoplasia
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1016/j.neo.2025.101133
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Cephalon
- Teva Pharmaceutical Industries
- Anika Therapeutics